Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.

@article{Lavallade2008ImatinibFN,
  title={Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.},
  author={Hugues de Lavallade and Jane F. Apperley and Jamshid S Khorashad and Dragana Milojkovic and Alistair G. Reid and Marco Bua and Richard M. Szydlo and Eduardo Olavarr{\'i}a and Jaspal Singh Kaeda and John M. Goldman and D. W. Marin},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2008},
  volume={26 20},
  pages={3358-63}
}
PURPOSE Imatinib is remarkably effective in treating newly diagnosed patients with chronic myeloid leukemia (CML) in chronic phase (CP). To date, most of the available data come from a single multicenter study in which some of the patients were censored for diverse reasons. Here, we report our experience in treating patients at a single institution in a setting where all events were recorded. PATIENTS AND METHODS A total of 204 consecutive adult patients with newly diagnosed CML in CP… CONTINUE READING
Highly Influential
This paper has highly influenced 13 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS